Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip™ Passes Animal Study
VClip ™ restores mitral valve function and overcomes limitations of current technologies
TEER is fast becoming the primary intervention for patients with mitral and tricuspid valve disease, however current marketed systems have limitations that often prevent optimal procedural outcomes or limit eligibility for certain patient groups. The VClipTM design intent is to address these unmet needs and provide better outcomes for patients.
Dr.
About
The Company’s lead product, DurAVRTM, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVRTM THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.
DurAVRTM THV is made using ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.
The ComASURTM Delivery System was designed to provide controlled deployment and accurate placement of the DurAVRTM THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.
Authorisation and Additional information
This announcement was authorised by the Board of Directors.
Website |
|
||
|
@AnterisTech |
|
|
|
|
||
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701929582/en/
For more information:
Investor Relations
investors@anteristech.com
+61 1300 550 310 | +61 7 3152 3200
Investor Relations (US)
Managing Director
+1 917 330 4269
Source: